Everything is becoming software and super-intelligent coding models can do anything in the physical world

Everything is becoming software and super-intelligent coding models can do anything in the physical world | The minute crisper arrived and you could edit the human genome, the human body becomes a software engineering problem. It's all just a software problem. At which point a coding model can do essentially anything in the physical world.

The minute crisper arrived and you could edit the human genome, the human body becomes a software engineering problem. It's all just a software problem. At which point a coding model can do essentially anything in the physical world.

Beneficiaries (24)

Adverse (6)

{
  "nia": false,
  "url": "https://www.youtube.com/watch?v=d__HRChE2ZE",
  "mode": "THESIS",
  "role": "Host",
  "context": "Everything's becoming software and when we have super intelligence solving all disease it's a software problem... Everything's becoming software. The minute crisper arrived and you could edit the human genome, the human body becomes a software engineering problem. It's all just a software problem. At which point a coding model can do essentially anything in the physical world.",
  "verbatim": "The minute crisper arrived and you could edit the human genome, the human body becomes a software engineering problem. It's all just a software problem. At which point a coding model can do essentially anything in the physical world.",
  "conv_cues": "essentially anything",
  "direction": "HAPPEN",
  "timeframe": "Future",
  "conv_level": "HIGH",
  "milestones": [
    {
      "kind": "llm_pre_event",
      "label": "150+ active CRISPR clinical trials globally",
      "source": "https://innovativegenomics.org/news/crispr-clinical-trials-2026/",
      "status": "hit",
      "weight": 0.4,
      "ordinal": -8,
      "source_id": null,
      "confidence": 0.95,
      "source_url": "https://innovativegenomics.org/news/crispr-clinical-trials-2026/",
      "expected_date": "2026-01-01",
      "observed_date": "2026-01-01",
      "research_origin": "deep_research",
      "measurement_criterion": "≥150 active CRISPR-based gene-editing therapy trials registered globally"
    },
    {
      "kind": "llm_pre_event",
      "label": "Casgevy (CRISPR/Cas9) approved in 10+ jurisdictions",
      "source": "https://innovativegenomics.org/news/crispr-clinical-trials-2026/ — IGI 2026 update",
      "status": "hit",
      "weight": 0.4,
      "ordinal": -7,
      "source_id": null,
      "confidence": 0.95,
      "source_url": "https://innovativegenomics.org/news/crispr-clinical-trials-2026/",
      "expected_date": "2026-04-01",
      "observed_date": "2026-04-01",
      "research_origin": "deep_research",
      "measurement_criterion": "Casgevy approved in US, UK, EU, Canada, Switzerland, Bahrain, Kuwait, Saudi Arabia, UAE"
    },
    {
      "kind": "quartile_checkpoint",
      "label": "Q1 window check-in (25%)",
      "status": "pending",
      "weight": 0.05,
      "ordinal": -6,
      "source_id": null,
      "expected_date": "2026-11-17",
      "observed_date": null
    },
    {
      "kind": "llm_pre_event",
      "label": "First in vivo CRISPR therapy approved (LNP/AAV delivery)",
      "notes": "In vivo delivery is the inflection point Wissner-Gross's thesis depends on — converts genome editing into a deliverable software target.",
      "source": "FDA approvals tracker, CRISPR Therapeutics + Intellia + Verve pipelines",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -5,
      "source_id": null,
      "confidence": 0.55,
      "expected_date": "2027-03-17",
      "research_origin": "deep_research",
      "expected_date_range": {
        "to": "2027-12-31",
        "from": "2026-06-01"
      },
      "measurement_criterion": "FDA or EMA approves first in vivo (non-ex-vivo) CRISPR therapy using LNP or viral delivery"
    },
    {
      "kind": "quartile_checkpoint",
      "label": "Q2 window check-in (50%)",
      "status": "pending",
      "weight": 0.05,
      "ordinal": -4,
      "source_id": null,
      "expected_date": "2027-06-06",
      "observed_date": null
    },
    {
      "kind": "llm_pre_event",
      "label": "AI/ML guide-RNA design tools become standard in CRISPR submissions",
      "source": "Nature Biotech, FDA INDs",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -3,
      "source_id": null,
      "confidence": 0.55,
      "expected_date": "2027-09-16",
      "research_origin": "training",
      "expected_date_range": {
        "to": "2028-12-31",
        "from": "2026-06-01"
      },
      "measurement_criterion": "≥50% of new CRISPR INDs cite AI/ML-designed guide RNAs (p
... (truncated)